517 related articles for article (PubMed ID: 17477094)
1. [Influence of combined, hypolipemic therapy on lipids and non-lipid atherosclerosis risk factors].
Broncel M; Balcerak M; Chojnowska-Jezierska J
Pol Merkur Lekarski; 2007 Jan; 22(127):62-5. PubMed ID: 17477094
[TBL] [Abstract][Full Text] [Related]
2. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
Guyton JR; Brown BG; Fazio S; Polis A; Tomassini JE; Tershakovec AM
J Am Coll Cardiol; 2008 Apr; 51(16):1564-72. PubMed ID: 18420099
[TBL] [Abstract][Full Text] [Related]
3. Coadministration of multidrug therapy to achieve lipid goals.
Denke MA
J Am Osteopath Assoc; 2004 Sep; 104(9 Suppl 7):S17-22. PubMed ID: 15467020
[TBL] [Abstract][Full Text] [Related]
4. LDL = 5: Virtues and dangers of multidrug therapy of low-density lipoprotein cholesterol.
Phillips W; Schaefer S
Prev Cardiol; 2010; 13(2):69-71. PubMed ID: 20377808
[TBL] [Abstract][Full Text] [Related]
5. Ezetimibe/simvastatin (INEGY) in the treatment of hyperlipidaemia.
Kastelein JJ; Sankatsing RR
Int J Clin Pract; 2005 Dec; 59(12):1464-71. PubMed ID: 16351680
[TBL] [Abstract][Full Text] [Related]
6. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
Hou R; Goldberg AC
Endocrinol Metab Clin North Am; 2009 Mar; 38(1):79-97. PubMed ID: 19217513
[TBL] [Abstract][Full Text] [Related]
7. Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy.
Duvall WL; Blazing MA; Saxena S; Guyton JR
J Cardiovasc Risk; 2002 Dec; 9(6):339-47. PubMed ID: 12478203
[TBL] [Abstract][Full Text] [Related]
8. Ezetimibe and recent clinical trials: a look on the bright side.
Ahmed MH
Expert Opin Drug Saf; 2010 Jul; 9(4):511-4. PubMed ID: 20377476
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials.
Birjmohun RS; Hutten BA; Kastelein JJ; Stroes ES
J Am Coll Cardiol; 2005 Jan; 45(2):185-97. PubMed ID: 15653014
[TBL] [Abstract][Full Text] [Related]
10. [How sure is the combined lipid lowering?].
Schäfer J
MMW Fortschr Med; 2005 Jan; 147(1-2):56. PubMed ID: 15704576
[No Abstract] [Full Text] [Related]
11. Safety of niacin and simvastatin combination therapy.
Bays H
Am J Cardiol; 2008 Apr; 101(8A):3B-8B. PubMed ID: 18375239
[TBL] [Abstract][Full Text] [Related]
12. Is there evidence-based hypolipidemic treatment with clinical benefit beyond statins?
Goumas GS
Angiology; 2009; 60(1):93-8. PubMed ID: 19019838
[TBL] [Abstract][Full Text] [Related]
13. [Favorable effects of decreasing lipids in patients with diabetes mellitus].
Gouni-Berthold I; Krone W
Dtsch Med Wochenschr; 2006 Dec; 131 Suppl 8():S252-4. PubMed ID: 17139581
[TBL] [Abstract][Full Text] [Related]
14. Statins as the cornerstone of drug therapy for dyslipidemia: monotherapy and combination therapy options.
Jones PH
Am Heart J; 2004 Jul; 148(1 Suppl):S9-13. PubMed ID: 15211327
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
Roeters van Lennep HW; Liem AH; Dunselman PH; Dallinga-Thie GM; Zwinderman AH; Jukema JW
Curr Med Res Opin; 2008 Mar; 24(3):685-94. PubMed ID: 18226326
[TBL] [Abstract][Full Text] [Related]
16. Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: results from two open-label extension studies in hypercholesterolemic patients.
Strony J; Hoffman R; Hanson M; Veltri E
Clin Ther; 2008 Dec; 30(12):2280-97. PubMed ID: 19167588
[TBL] [Abstract][Full Text] [Related]
17. [Therapy of dyslipidemia in post-infarction: state of the art].
Borgia MC; Nardi M; Da Ros S; Castellano V
Clin Ter; 2007; 158(6):523-32. PubMed ID: 18265719
[TBL] [Abstract][Full Text] [Related]
18. Treatment of high-risk older persons with lipid-lowering drug therapy.
Aronow WS
Am J Ther; 2008; 15(2):102-7. PubMed ID: 18356628
[TBL] [Abstract][Full Text] [Related]
19. [Dual inhibition of cholesterol using the drug combination ezetimibe/simvastatin?].
Vaverková H
Vnitr Lek; 2007 Apr; 53(4):421-7. PubMed ID: 17578178
[TBL] [Abstract][Full Text] [Related]
20. The role of ezetimibe in the prevention of cardiovascular disease: where do we stand after ARBITER 6-HALTS.
Howard WJ
Nutr Metab Cardiovasc Dis; 2010 Jun; 20(5):295-300. PubMed ID: 20556890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
